218 related articles for article (PubMed ID: 36295630)
1. miRNA Expression Associated with HbF in Saudi Sickle Cell Anemia.
Cyrus C; Vatte C; Al-Nafie A; Chathoth S; Akhtar MS; Darwish M; Almohazey D; AlDubayan SH; Steinberg MH; Al-Ali A
Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295630
[No Abstract] [Full Text] [Related]
2. Fetal hemoglobin in sickle cell anemia: The Arab-Indian haplotype and new therapeutic agents.
Habara AH; Shaikho EM; Steinberg MH
Am J Hematol; 2017 Nov; 92(11):1233-1242. PubMed ID: 28736939
[TBL] [Abstract][Full Text] [Related]
3. Role of microRNA in hydroxyurea mediated HbF induction in sickle cell anaemia patients.
Kargutkar N; Sawant-Mulay M; Hariharan P; Chandrakala S; Nadkarni A
Sci Rep; 2023 Jan; 13(1):369. PubMed ID: 36611033
[TBL] [Abstract][Full Text] [Related]
4. MIR-144-mediated NRF2 gene silencing inhibits fetal hemoglobin expression in sickle cell disease.
Li B; Zhu X; Ward CM; Starlard-Davenport A; Takezaki M; Berry A; Ward A; Wilder C; Neunert C; Kutlar A; Pace BS
Exp Hematol; 2019 Feb; 70():85-96.e5. PubMed ID: 30412705
[TBL] [Abstract][Full Text] [Related]
5. Targeting fetal hemoglobin expression to treat β hemoglobinopathies.
Steinberg MH
Expert Opin Ther Targets; 2022 Apr; 26(4):347-359. PubMed ID: 35418266
[TBL] [Abstract][Full Text] [Related]
6. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.
Traxler EA; Yao Y; Wang YD; Woodard KJ; Kurita R; Nakamura Y; Hughes JR; Hardison RC; Blobel GA; Li C; Weiss MJ
Nat Med; 2016 Sep; 22(9):987-90. PubMed ID: 27525524
[TBL] [Abstract][Full Text] [Related]
7. Featured Article: Modulation of fetal hemoglobin in hereditary persistence of fetal hemoglobin deletion type-2, compared to Sicilian δβ-thalassemia, by BCL11A and SOX6-targeting microRNAs.
Fornari TA; Lanaro C; Albuquerque DM; Ferreira R; Costa FF
Exp Biol Med (Maywood); 2017 Feb; 242(3):267-274. PubMed ID: 27591578
[TBL] [Abstract][Full Text] [Related]
8. Bach1 inhibitor HPP-D mediates γ-globin gene activation in sickle erythroid progenitors.
Palani CD; Zhu X; Alagar M; Attucks OC; Pace BS
Blood Cells Mol Dis; 2024 Jan; 104():102792. PubMed ID: 37633023
[TBL] [Abstract][Full Text] [Related]
9. Fetal hemoglobin in sickle cell anemia: genetic studies of the Arab-Indian haplotype.
Ngo D; Bae H; Steinberg MH; Sebastiani P; Solovieff N; Baldwin CT; Melista E; Safaya S; Farrer LA; Al-Suliman AM; Albuali WH; Al Bagshi MH; Naserullah Z; Akinsheye I; Gallagher P; Luo HY; Chui DH; Farrell JJ; Al-Ali AK; Alsultan A
Blood Cells Mol Dis; 2013 Jun; 51(1):22-6. PubMed ID: 23465615
[TBL] [Abstract][Full Text] [Related]
10. The Role of miRNAs as Therapeutic Tools in Sickle Cell Disease.
Cyrus C
Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684143
[No Abstract] [Full Text] [Related]
11. Cilostazol-mediated reversion of γ-globin silencing is associated with a high level of HbF production: A potential therapeutic candidate for β-globin disorders.
Ali H; Khan F; Musharraf SG
Biomed Pharmacother; 2021 Oct; 142():112058. PubMed ID: 34426256
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-96 directly inhibits γ-globin expression in human erythropoiesis.
Azzouzi I; Moest H; Winkler J; Fauchère JC; Gerber AP; Wollscheid B; Stoffel M; Schmugge M; Speer O
PLoS One; 2011; 6(7):e22838. PubMed ID: 21829531
[TBL] [Abstract][Full Text] [Related]
13. 14q32 and let-7 microRNAs regulate transcriptional networks in fetal and adult human erythroblasts.
Lessard S; Beaudoin M; Orkin SH; Bauer DE; Lettre G
Hum Mol Genet; 2018 Apr; 27(8):1411-1420. PubMed ID: 29432581
[TBL] [Abstract][Full Text] [Related]
14. Erythrocyte microRNAs: a tiny magic bullet with great potential for sickle cell disease therapy.
Verma HK; Ratre YK; Bhaskar LVKS; Colombatti R
Ann Hematol; 2021 Mar; 100(3):607-614. PubMed ID: 33398452
[TBL] [Abstract][Full Text] [Related]
15. A candidate transacting modulator of fetal hemoglobin gene expression in the Arab-Indian haplotype of sickle cell anemia.
Vathipadiekal V; Farrell JJ; Wang S; Edward HL; Shappell H; Al-Rubaish AM; Al-Muhanna F; Naserullah Z; Alsuliman A; Qutub HO; Simkin I; Farrer LA; Jiang Z; Luo HY; Huang S; Mostoslavsky G; Murphy GJ; Patra PK; Chui DH; Alsultan A; Al-Ali AK; Sebastiani P; Steinberg MH
Am J Hematol; 2016 Nov; 91(11):1118-1122. PubMed ID: 27501013
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.
Pule GD; Mowla S; Novitzky N; Wiysonge CS; Wonkam A
Expert Rev Hematol; 2015 Oct; 8(5):669-79. PubMed ID: 26327494
[TBL] [Abstract][Full Text] [Related]
17. PUM1 mediates the posttranscriptional regulation of human fetal hemoglobin.
Elagooz R; Dhara AR; Gott RM; Adams SE; White RA; Ghosh A; Ganguly S; Man Y; Owusu-Ansah A; Mian OY; Gurkan UA; Komar AA; Ramamoorthy M; Gnanapragasam MN
Blood Adv; 2022 Dec; 6(23):6016-6022. PubMed ID: 35667093
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia.
Walker AL; Steward S; Howard TA; Mortier N; Smeltzer M; Wang YD; Ware RE
Blood; 2011 Nov; 118(20):5664-70. PubMed ID: 21921042
[TBL] [Abstract][Full Text] [Related]
19. Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons.
Rivers A; Vaitkus K; Jagadeeswaran R; Ruiz MA; Ibanez V; Ciceri F; Cavalcanti F; Molokie RE; Saunthararajah Y; Engel JD; DeSimone J; Lavelle D
Exp Hematol; 2018 Nov; 67():60-64.e2. PubMed ID: 30125603
[TBL] [Abstract][Full Text] [Related]
20. The genetics of hemoglobin A2 regulation in sickle cell anemia.
Griffin PJ; Sebastiani P; Edward H; Baldwin CT; Gladwin MT; Gordeuk VR; Chui DH; Steinberg MH
Am J Hematol; 2014 Nov; 89(11):1019-23. PubMed ID: 25042611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
